Pyridoxamine Supplement Sale Should Cease Following IND Filing - Petition
This article was originally published in The Tan Sheet
Executive Summary
Dietary supplements containing pyridoxamine should be removed from the market following the filing of an investigational new drug application for the ingredient, according to a citizen petition filed July 29
You may also be interested in...
BioStratum Challenges Affidavit Asserting Pre-1994 Pyridoxamine Product
Hopeful pyridoxamine drug marketer BioStratum is skeptical of an affidavit submitted to FDA by Jarrow Formulas as evidence of the pre-1994 sale of pyridoxamine in supplements
Pyridoxamine Debate Prompts FDA Comment Period
FDA tentatively has concluded that pyridoxamine is not a dietary supplement and has opened a 30-day comment period inviting information on the ingredient's prior marketing as a dietary ingredient or food
BioStratum, CRN Spar Over Pyridoxamine’s Pre-DSHEA Marketing Status
BioStratum insists there is no evidence supporting the Council for Responsible Nutrition's claim that pyridoxamine was sold as a dietary ingredient before 1994 and says the ingredient should not be considered "grandfathered" under DSHEA